PKM and neoplasm: As shown in Fig 7A, tumors responding to shRNA-PKM2 therapy demonstrated a significant decrease in cytosolic PKM2 in shRNA-PKM2 treated mice xenografts (regressing) compared to parental or non-responding tumor xenografts (non-regressing) (P≤0.01).